Document is current
Any future updates will be listed below
-
Authors
Jeppsson, A.
Sandelius, Å.
Zettergren, A.
Kern, S.
Skoog, I.
Blennow, K.
Zetterberg, H.
Wikkelsø, C.
Hellström, P.
Tullberg, M. https://orcid.org/0000-0003-4997-5266
-
Funding
Funding for this research was provided by:
Edit Jacobsson donation fund
Rune and Ulla Amlöv foundation
the foundation Hjalmar Svenssons forskningsfond
the Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement
the Swedish Research Council
Hjärnfonden, Sweden
Alzheimerfonden
University of Gothenburg
- License Information
-
More Information
Article History
Received: 14 March 2023
Accepted: 23 June 2023
First Online: 6 July 2023
Declarations
:
: The Ethics Committee for Medical Research at Gothenburg University approved all studies.Written informed consent was obtained from all participants, their nearest relatives, or both, in accordance with the Declaration of Helsinki.
: All authors approved the final manuscript for publication.
: SK has served at scientific advisory boards and/or as consultant for Geras Solutions and Biogen. KB has served as a consultant and at advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Julius Clinical, Lilly, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for Biogen, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). CW and MT have received honoraria for lecturing from IntegraLife. AJ, ÅS, SK, PH and IS have no conflict of interest to report.
